South Carolina Patient Completed Ovarian Cancer Trial
A South Carolina woman recently showed no signs of cancer after participating in a specialized clinical trial.
Updated on Oct. 2, 2026 in Cancer
Debra Jean Chandler received a Stage 4 ovarian cancer diagnosis in October 2024 and subsequently underwent an intensive treatment regimen. Following cytoreductive surgery performed in February 2025, she completed a specialized clinical trial and now shows no evidence of disease.
Why it matters
The clinical trial investigates whether adding heated intraperitoneal chemotherapy to standard surgical procedures can effectively delay or prevent the recurrence of ovarian cancer. Researchers are collecting data to compare survival rates and side effects between patient groups.
Trial participants receive niraparib as maintenance therapy for up to 3 years. The study compares patient groups undergoing cytoreductive surgery with or without heated intraperitoneal chemotherapy.
The players
Debra Jean Chandler
She is a South Carolina resident who participated in a clinical trial for advanced ovarian cancer.
Brian Orr
He is a surgical specialist who performed the cytoreductive surgery as part of the patient's care.
MUSC Hollings Cancer Center
This Charleston-based institution provides specialized oncology research and patient care services.
McLeod Regional Medical Center
This healthcare facility in Florence coordinated oncology care for the patient's treatment plan.
The details
Chandler's care involved coordination between MUSC Hollings Cancer Center and McLeod Regional Medical Center. After receiving four rounds of initial chemotherapy and undergoing surgery, she completed two additional rounds of treatment to reach her current disease-free status.
Timeline
October 2024: Chandler received her Stage 4 ovarian cancer diagnosis.
February 2025: Brian Orr performed cytoreductive surgery on the patient.
Health Landscape
The Heated Ovarian Treatment Trial represents a shift toward aggressive, localized chemotherapy delivery during surgery. This approach aims to surpass traditional surgical outcomes by addressing residual microscopic disease more effectively.
Patients diagnosed with advanced ovarian cancer may have access to new clinical trial protocols that combine surgery with specialized chemotherapy techniques. These options can significantly alter treatment plans and recovery expectations for those in similar medical circumstances.
The takeaway
Clinical trials offer patients access to emerging therapeutic combinations that may improve long-term outcomes in cases of advanced disease. Patients are encouraged to discuss emerging treatment protocols and trial eligibility with their primary oncology teams.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by Post and Courier.
